Search
Dirucotide
go.drugbank.com/drugs/DB04921InvestigationalIn particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans. … Dirucotide has been developed for the treatment of multiple sclerosis (MS). Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp.
Navepegritide
go.drugbank.com/drugs/DB17824ApprovedInvestigational[L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065] … endochondral ossification, resulting in multisystem complications including short stature.
Fezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigational[A259542] Although previous NK3 receptor antagonists exist, such as osanetant and talnetant, only fezolinetant showed tangible effects on the HPC axis, potentially due to its favorable pharmacokinetics … Women undergoing abrupt menopause due to oophorectomy also experienced more severe symptoms than those going through a gradual transition.
RPI-MN
go.drugbank.com/drugs/DB17957ExperimentalRPI-MN is a detoxified or chemically modified alpha-cobratoxin with antiviral properties.
Synonyms: RPI-MNEnlicitide
go.drugbank.com/drugs/DB22580ApprovedInvestigationalAcross two 52-week placebo-controlled trials, enlicitide 20 mg once daily reduced LDL-C at Week 24 by 56% relative to placebo in patients with hypercholesterolemia at established or increased ASCVD risk … [L63795] Enlicitide is indicated as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), and was studied in
Streptococcus pneumoniae type 15b capsular polysaccharide antigen
go.drugbank.com/drugs/DB10333ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADETTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalRenal cell carcinoma (RCC) is responsible for 3% of cancer cases[A231314] and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. … It was approved on March 10, 2021 by the FDA. Marketed by Aveo Oncology, tivozanib is a promising therapy for individuals with RCC who have not been treated successfully with other therapies.[L32524]
Etorphine
go.drugbank.com/drugs/DB01497ExperimentalIllicitVet approvedA narcotic analgesic morphinan used as a sedative in veterinary practice. … In certain countries, etorphine is classified as a Schedule 1 drug and hence, in these countries, it can be used legally only by health professionals and for research purposes.
Brilliant green cation
go.drugbank.com/drugs/DB11279ApprovedVet approvedDue to its inhibitory actions against Gram positive microorganisms, brilliant green can be found in antiseptic products such as solutions and swabs used to prevent infection.
Mixtures: Kerr 100 Triple Dye Dispos-ACategories: Compounds used in a research, industrial, or household setting